Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer’s Prevenar 13 vaccine receives European approval

Pfizer’s Prevenar 13 vaccine receives European approval

12th July 2013

Pfizer has received approval for its Prevenar 13 vaccine to be used by adults aged between 18 and 49 in the European Union.

The pneumococcal conjugate vaccination provides immunisation against invasive diseases caused by the Streptococcus pneumoniae bacterium. These include meningitis, pneumonia and septicaemia.

Previously, the vaccine was permitted for use in children from six weeks to 17 years old and adults aged 50 and over, but the European Commission is the first to extend this to allow it to be used at any age.

Emilio Emini, chief scientific officer for vaccine research at Pfizer, said: "Today’s European approval for the expanded use of Prevenar 13 is a testament to Pfizer’s continued commitment to developing innovative vaccines that can help prevent serious – and sometimes fatal – disease through every stage of life."

The preventative treatment is approved for use in young children in more than 120 countries worldwide and for adults aged 50 or over in 80 countries. ADNFCR-8000103-ID-801611517-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.